Evaluation of potential drug‐drug interaction risk of pexidartinib with substrates of cytochrome P450 and P‐glycoprotein
H Zahir, F Kobayashi, C Zamora… - The Journal of …, 2021 - Wiley Online Library
Pexidartinib is approved for treatment of adults with symptomatic tenosynovial giant cell
tumor. In vitro data showed pexidartinib's potential to inhibit and induce cytochrome P450 …
tumor. In vitro data showed pexidartinib's potential to inhibit and induce cytochrome P450 …
Pharmacokinetics of the Multi‐kinase Inhibitor Pexidartinib: Mass Balance and Dose Proportionality
H Zahir, J Greenberg, C Hsu… - Clinical …, 2023 - Wiley Online Library
Pexidartinib is an oral small‐molecule tyrosine kinase inhibitor that selectively targets colony‐
stimulating factor 1 receptor. Two phase 1 single‐center trials were conducted in healthy …
stimulating factor 1 receptor. Two phase 1 single‐center trials were conducted in healthy …
[HTML][HTML] Evaluation of Absorption and Metabolism-Based DDI Potential of Pexidartinib in Healthy Subjects
H Zahir, J Greenberg, D Shuster, C Hsu… - Clinical …, 2022 - Springer
Abstract Background and Objective Pexidartinib is a novel oral small-molecule inhibitor that
selectively targets colony-stimulating factor 1 receptor, KIT proto-oncogene receptor tyrosine …
selectively targets colony-stimulating factor 1 receptor, KIT proto-oncogene receptor tyrosine …
Effect of mild and moderate hepatic impairment (defined by Child–Pugh classification and National Cancer Institute Organ Dysfunction Working Group criteria) on …
H Zahir, J Greenberg, C Hsu… - The Journal of …, 2022 - Wiley Online Library
Pexidartinib is a novel oral small‐molecule tyrosine kinase inhibitor targeting the colony‐
stimulating factor 1 receptor. Pexidartinib undergoes extensive hepatic metabolism via …
stimulating factor 1 receptor. Pexidartinib undergoes extensive hepatic metabolism via …
Exploring the Effect of Compound Glycyrrhizin and Silybinin on the Metabolism of Pexidartinib in Rats Based on CYP3A4 and CYP2C9
Y Su, X Wei, Q Cheng, H Qi, J Chen… - … in Pharmacological and …, 2023 - Wiley Online Library
Pexidartinib offered a new therapeutic option for adult patients with symptomatic
tenosynovial giant cell tumor (TGCT) who were refractory to surgical treatment and had …
tenosynovial giant cell tumor (TGCT) who were refractory to surgical treatment and had …
Exposure–response analysis of efficacy and safety for pexidartinib in patients with tenosynovial giant cell tumor
O Yin, H Zahir, J French, D Polhamus… - CPT …, 2021 - Wiley Online Library
This analysis was conducted to assess exposure–response relationships for efficacy and
safety of pexidartinib in patients with tenosynovial giant cell tumor. Efficacy was assessed …
safety of pexidartinib in patients with tenosynovial giant cell tumor. Efficacy was assessed …
Population pharmacokinetic analysis of pexidartinib in healthy subjects and patients with tenosynovial giant cell tumor or other solid tumors
O Yin, AJ Wagner, J Kang, W Knebel… - The Journal of …, 2021 - Wiley Online Library
Pexidartinib is a kinase inhibitor that induces tumor response and improvements in
symptoms and functional outcomes in adult patients with symptomatic tenosynovial giant cell …
symptoms and functional outcomes in adult patients with symptomatic tenosynovial giant cell …
Dosing recommendation based on the effects of different meal types on pexidartinib pharmacokinetics in healthy subjects: implementation of model‐informed drug …
H Zahir, O Yin, C Hsu, AJ Wagner… - Clinical …, 2023 - Wiley Online Library
Pexidartinib, an oral small molecule inhibitor of the colony‐stimulating factor 1 receptor, is
approved for treatment of adults with symptomatic tenosynovial giant cell tumor associated …
approved for treatment of adults with symptomatic tenosynovial giant cell tumor associated …
[HTML][HTML] Supporting patients in the transition to the revised pexidartinib dosing regimen: perspectives from the multidisciplinary clinical and allied health professional …
C McCabe, H Wright, K Polson, AJ Wagner - Orphanet Journal of Rare …, 2023 - Springer
Pexidartinib is a colony-stimulating factor-1 receptor inhibitor approved in the United States
for treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) …
for treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) …
[HTML][HTML] Eco-Friendly, Simple, Fast, and Sensitive UPLC-MS/MS Method for Determination of Pexidartinib in Plasma and Its Application to Metabolic Stability
E Ezzeldin, M Iqbal, YA Asiri, GAE Mostafa, AYA Sayed - Molecules, 2022 - mdpi.com
Pexidartinib is the first drug approved by the US Food and Drug Administration specifically to
treat the rare joint tumor tenosynovial giant cell tumor. In the current study, a validated …
treat the rare joint tumor tenosynovial giant cell tumor. In the current study, a validated …